Healthcare -
Biotechnology - NASDAQ - US
$ 0.82
0.737 %
$ 3.53 M
Market Cap
-0.1
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Bio-Path Holdings, Inc.
| Current Assets | 3.04 M |
| Cash & Short-Term Investments | 1.05 M |
| Receivables | 0 |
| Other Current Assets | 1.99 M |
| Non-Current Assets | 178 K |
| Long-Term Investments | 0 |
| PP&E | 178 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 1.91 M |
| Accounts Payable | 457 K |
| Short-Term Debt | 103 K |
| Other Current Liabilities | 1.35 M |
| Non-Current Liabilities | 873 K |
| Long-Term Debt | 10 K |
| Other Non-Current Liabilities | 863 K |
EFFICIENCY
Earnings Waterfall
Bio-Path Holdings, Inc.
| Revenue | 0 |
| Cost Of Revenue | 178 K |
| Gross Profit | -178 K |
| Operating Expenses | 15.8 M |
| Operating Income | -15.8 M |
| Other Expenses | 235 K |
| Net Income | -16.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Bio-Path Holdings, Inc.
| Net Income | -16.1 M |
| Depreciation & Amortization | 178 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 734 K |
| Change in Working Capital | 3.13 M |
| Others | 3.4 M |
| Free Cash Flow | -11.5 M |
Wall Street Analysts Price Targets
Bio-Path Holdings, Inc.
BPTH has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
BPTH does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Bio-Path Holdings, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
6 years ago
Jan 18, 2019
|
Sell 172 K
USD
|
ARMISTICE CAPITAL, LLC
10 percent owner
|
- 64457
|
2.6629 USD |
|
6 years ago
Jan 18, 2019
|
Sell 0
USD
|
ARMISTICE CAPITAL, LLC
10 percent owner
|
- 0
|
0 USD |
|
9 years ago
Jul 13, 2015
|
Bought
8.96 K USD
|
Garrison Michael J.
Director
|
+ 7343
|
1.22 USD |
|
9 years ago
Jul 09, 2015
|
Bought
10.2 K USD
|
Garrison Michael J.
Director
|
+ 8724
|
1.17 USD |
|
9 years ago
Jul 08, 2015
|
Bought
25.2 K USD
|
Garrison Michael J.
Director
|
+ 21015
|
1.2 USD |
|
9 years ago
Jul 07, 2015
|
Bought
46 K USD
|
Garrison Michael J.
Director
|
+ 38985
|
1.1801 USD |
|
11 years ago
Jun 12, 2013
|
Bought
102 K USD
|
Garrison Michael J.
Director
|
+ 340000
|
0.3 USD |
|
15 years ago
Dec 02, 2009
|
Bought
87.5 K USD
|
Garrison Thomas E
Director
|
+ 350000
|
0.25 USD |
|
15 years ago
Oct 13, 2009
|
Bought
600 K USD
|
Garrison Thomas E
Director
|
+ 400000
|
1.5 USD |
|
15 years ago
Dec 02, 2009
|
Bought
525 K USD
|
Garrison Thomas E
Director
|
+ 350000
|
1.5 USD |
|
15 years ago
Oct 13, 2009
|
Bought
100 K USD
|
Garrison Thomas E
Director
|
+ 400000
|
0.25 USD |
|
15 years ago
Oct 13, 2009
|
Bought
600 K USD
|
Garrison Thomas E
Director
|
+ 400000
|
1.5 USD |
7. News
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 Diabetes Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 Diabetes
globenewswire.com
- 1 month ago
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24
Dallas, Texas--(Newsfile Corp. - December 13, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q3 2024. To view the full announcement, including downloadable images, bios, and more, click here.
newsfilecorp.com
- 1 month ago
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance
globenewswire.com
- 1 month ago
All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy
Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 1 month ago
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Bio-Path (BPTH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
zacks.com
- 1 month ago
Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2024 Earnings Conference Call November 15, 2024 8:30 AM ET Company Participants Will O'Connor - Managing Director & Team Lead, Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Operator Good morning and welcome to the Bio-Path Holdings, Incorporated Third Quarter 2024 Conference Call. All participants will be in listen-only mode.
seekingalpha.com
- 2 months ago
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
Expands DNAbilize ® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments.
globenewswire.com
- 2 months ago
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview.
globenewswire.com
- 2 months ago
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of an aggregate of 4,597,702 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 6,407,657 shares of common stock and short-term series B warrants to purchase up to 6,407,657 shares of common stock at a purchase price of $0.87 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement. The series A warrants and short-term series B warrants have an exercise price of $1.00 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the “Stockholder Approval Date”). The series A warrants will expire five years from the Stockholder Approval Date and the short-term series B warrants will expire twenty-four months from the Stockholder Approval Date.
globenewswire.com
- 3 months ago
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 4,597,702 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 6,407,657 shares of common stock and short-term series B warrants to purchase up to 6,407,657 shares of common stock at a purchase price of $0.87 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.00 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the “Stockholder Approval Date”). The series A warrants will expire five years from the Stockholder Approval Date and the short-term series B warrants will expire twenty-four months from the Stockholder Approval Date. The closing of the offering is expected to occur on or about October 10, 2024, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 3 months ago
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the initiation of a therapeutic program to develop BP1001-A for the treatment of obesity and related metabolic diseases. This program marks the first application of DNAbilize technology for development of a non-cancer application, which highlights the broad therapeutic potential of this technology.
globenewswire.com
- 3 months ago
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2024. To view the full announcement, including downloadable images, bios, and more, click here.
newsfilecorp.com
- 4 months ago
8. Profile
Summary
Bio-Path Holdings, Inc. BPTH
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 3.53 M
Dividend Yield
0.00%
Description
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Contact
4710 Bellaire Boulevard, Bellaire, TX, 77401
https://www.biopathholdings.com
IPO
Date
March 4, 2008
Employees
10
Officers
Mr. Peter H. Nielsen MBA
Co-Founder, Chairman of the Board, Chief Executive Officer, President, Chief Financial Officer & Treasurer
Mr. Anthony Price
Senior Vice President of Finance, Accounting & Administration
Mr. Douglas P. Morris
Co-Founder, Director of Investor Relations, Secretary & Director
Dr. Ana Tari Ashizawa M.B.A., MBA, Ph.D.
Senior Vice President of Research, Development & Clinical Design
Mr. Michael Hickey M.B.A.
Vice President of Clinical Operations